Sponsors (9)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
The bill promises better-targeted research, coordinated NIH effort, and potential health and inclusion benefits for people with Down syndrome, but it raises trade-offs around federal cost/prioritization, participant privacy, and the risk of reinforcing medicalized stigma unless paired with funding, data safeguards, and anti-stigma measures.
People with Down syndrome and their families gain stronger, targeted research and expanded inclusion in clinical trials, increasing prospects for better diagnosis, treatments, and quality of life.
A centralized, coordinated NIH study population and biennial reporting to Congress will improve research efficiency, data sharing, and transparency for clinicians, researchers, and patients.
Greater recognition of the capabilities and needs of people with Down syndrome can reduce stigma and support inclusion in education, employment, and civic life.
Expanding targeted research and building a large study cohort will likely increase NIH spending and could divert funds from other research priorities, raising opportunity costs for taxpayers and other patient communities.
Collecting and maintaining a large study population and real-world evidence creates privacy and data-security risks for participants if protections are not robustly implemented.
Passing findings and studies without committing new funding or services could create expectations for improved care or programs that may go unmet.
Creates an NIH-led research program to coordinate and fund research specifically focused on Down syndrome. The program directs NIH to support basic and translational science on chromosome 21, build and maintain a large study population of people with Down syndrome, expand clinical trials that include or target people with Down syndrome, investigate biological mechanisms and biomarkers for co-occurring conditions, provide technical assistance to grantees, and report to Congress every two years on research activities and real-world evidence. The text is an authorization to establish and prioritize this research agenda and interagency coordination; it does not itself appropriate specific funds or set implementation deadlines beyond the reporting requirement.
Introduced May 21, 2025 by John Wright Hickenlooper · Last progress May 21, 2025